Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Pmd-107: Marizomib, Pomalidomide and Low Dose-Dexamethasone Combination Study in Relapsed/Refractory Multiple Myeloma (NCT02103335): Full Enrollment Results from a Phase-1 Multicenter, Open Label Study

Andrew Spencer, Simon Harrison, MBBS MRCP(UK) FRCPath(UK) FRACP PhD, Jacob P. Laubach, MD, Jeffrey Zonder, MD, Ashraf Z Badros, MD, Krystal Bergin, Amit Khot, MD, Todd Zimmerman, MD, Kenneth C. Anderson, MD, Ann MacLaren, PhD, Steven D Reich, MD, Mohit Trikha, PhD, Paul G. Richardson, MD

Blood (2016) 128 (22): 3326.

https://doi.org/10.1182/blood.V128.22.3326.3326

Published: 2016

Journal Articles

Phase 1, Multicenter, Open-Label, Combination Study (NPI-0052-107; NCT02103335) of Pomalidomide (POM), Marizomib (MRZ, NPI-0052), and Low-Dose Dexamethasone (LD-DEX) in Patients with Relapsed and Refractory Multiple Myeloma

Andrew Spencer, Jacob P. Laubach, MD, Jeffrey A Zonder, MD, Ashraf Z Badros, MD, Simon Harrison, MD, Amit Khot, MD, Dharminder Chauhan, PhD, Kenneth C. Anderson, MD, Steven D Reich, MD, Mohit Trikha, PhD, Paul G. Richardson, MD

Blood (2015) 126 (23): 4220.

https://doi.org/10.1182/blood.V126.23.4220.4220

Published: 2015

Journal Articles

Marizomib Overcomes Compensatory Hyperactivation of Trypsin-like and Caspase-like Subunits to Provide Pan-Proteasome Subunit Inhibition in Patients with Multiple Myeloma and Solid Tumors

Andrew Spencer, Simon Harrison, MD, Francis Burrows, Paul Mainwaring, MD, Timothy Price, MD, Michael J Millward, MD, Peeter Padrik, MD, Craig Underhill, MD, Paul Cannell, MD, Steven D Reich, MD, Mohit Trikha, PhD

Blood (2015) 126 (23): 5375.

https://doi.org/10.1182/blood.V126.23.5375.5375

Published: 2015

Journal Articles

Results from the Phase I Portion of a Phase I/II Study of ATN-224 and Bortezomib for Patients with Multiple Myeloma Relapsed from or Refractory to Bortezomib

James R. Berenson, MD, Thomas Ervin, MD, Ralph V. Boccia, MD, Olcay Batuman, MD, Regina Swift, RN, Christina DiLauro Abaya, BA, Andrew P. Mazar, PhD, Gilad S. Gordon, MD, Steven D. Reich, MD, Jennifer A. Callahan, BA

Blood (2008) 112 (11): 5185.

https://doi.org/10.1182/blood.V112.11.5185.5185

Published: 2008

Journal Articles

Phase I Study of the [Cu, Zn] Superoxide Dismutase (SOD1) Inhibitor ATN-224 (Bis-Choline Tetrathiomolybdate) in Patients (pts) with Advanced Hematologic Malignancies.

James R. Berenson, MD, Ralph Vincent Boccia, MD, Asad Bashey, MD PhD, Alexandra M. Levine, MD, Omer N. Koc, MD, Jennifer A. Callahan, Andrew P. Mazar, PhD, Steven D. Reich, MD

Blood (2006) 108 (11): 2593.

https://doi.org/10.1182/blood.V108.11.2593.2593

Published: 2006

Journal Articles

Phase 2 Study of the Anti-Angiogenesis Agent AG-013736 in Patients with Poor Prognosis Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS).

Francis J. Giles, MD, Heidi Steinfeldt, William T. Bellamy, MD, Paul Bycott, PhD, Yazdi Pithavala, PhD, Steven D. Reich, MD, Alan F. List, MD

Blood (2004) 104 (11): 1813.

https://doi.org/10.1182/blood.V104.11.1813.1813

Published: 2004

NARROW

Pmd-107: Marizomib, Pomalidomide and Low Dose-Dexamethasone Combination Study in Relapsed/Refractory Multiple Myeloma (NCT02103335): Full Enrollment Results from a Phase-1 Multicenter, Open Label Study

Phase 1, Multicenter, Open-Label, Combination Study (NPI-0052-107; NCT02103335) of Pomalidomide (POM), Marizomib (MRZ, NPI-0052), and Low-Dose Dexamethasone (LD-DEX) in Patients with Relapsed and Refractory Multiple Myeloma

Marizomib Overcomes Compensatory Hyperactivation of Trypsin-like and Caspase-like Subunits to Provide Pan-Proteasome Subunit Inhibition in Patients with Multiple Myeloma and Solid Tumors

Results from the Phase I Portion of a Phase I/II Study of ATN-224 and Bortezomib for Patients with Multiple Myeloma Relapsed from or Refractory to Bortezomib

Phase I Study of the [Cu, Zn] Superoxide Dismutase (SOD1) Inhibitor ATN-224 (Bis-Choline Tetrathiomolybdate) in Patients (pts) with Advanced Hematologic Malignancies.

Phase 2 Study of the Anti-Angiogenesis Agent AG-013736 in Patients with Poor Prognosis Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS).

Email alerts

ASH Publications

American Society of Hematology

Pmd-107: Marizomib, Pomalidomide and Low Dose-Dexamethasone Combination Study in Relapsed/Refractory Multiple Myeloma (NCT02103335): Full Enrollment Results from a Phase-1 Multicenter, Open Label Study

Phase 1, Multicenter, Open-Label, Combination Study (NPI-0052-107; NCT02103335) of Pomalidomide (POM), Marizomib (MRZ, NPI-0052), and Low-Dose Dexamethasone (LD-DEX) in Patients with Relapsed and Refractory Multiple Myeloma

Marizomib Overcomes Compensatory Hyperactivation of Trypsin-like and Caspase-like Subunits to Provide Pan-Proteasome Subunit Inhibition in Patients with Multiple Myeloma and Solid Tumors

Results from the Phase I Portion of a Phase I/II Study of ATN-224 and Bortezomib for Patients with Multiple Myeloma Relapsed from or Refractory to Bortezomib

Phase I Study of the [Cu, Zn] Superoxide Dismutase (SOD1) Inhibitor ATN-224 (Bis-Choline Tetrathiomolybdate) in Patients (pts) with Advanced Hematologic Malignancies.

Phase 2 Study of the Anti-Angiogenesis Agent AG-013736 in Patients with Poor Prognosis Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only